Astrazeneca Plc (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 58,739,000 | 54,073,000 | 45,811,000 | 44,351,000 | 37,417,000 |
| Cost of Goods | 10,633,000 | 10,207,000 | 8,268,000 | 12,391,000 | 12,437,000 |
| Gross Profit | 48,106,000 | 43,866,000 | 37,543,000 | 31,960,000 | 24,980,000 |
| Operating Expenses | 34,363,000 | 33,863,000 | 29,350,000 | 28,203,000 | 23,924,000 |
| Operating Income | 13,743,000 | 10,003,000 | 8,193,000 | 3,757,000 | 1,056,000 |
| Interest Expense | 1,694,000 | 1,742,000 | 1,626,000 | 1,346,000 | 1,300,000 |
| Other Income | 353,000 | 430,000 | 332,000 | 90,000 | -21,000 |
| Pre-tax Income | 12,402,000 | 8,691,000 | 6,899,000 | 2,501,000 | -265,000 |
| Income Tax | 2,169,000 | 1,650,000 | 938,000 | -792,000 | -380,000 |
| Net Income Continuous | 10,233,000 | 7,041,000 | 5,961,000 | 3,293,000 | 115,000 |
| Minority Interests | 8,000 | 6,000 | 6,000 | 5,000 | 3,000 |
| Net Income | $10,225,000 | $7,035,000 | $5,955,000 | $3,288,000 | $112,000 |
| EPS Basic Total Ops | 3.30 | 2.27 | 3.84 | 2.12 | 0.08 |
| EPS Basic Continuous Ops | 3.30 | 2.27 | 3.85 | 2.13 | 0.08 |
| EPS Diluted Total Ops | 3.27 | 2.25 | 3.81 | 2.11 | 0.08 |
| EPS Diluted Continuous Ops | 3.28 | 2.25 | 3.82 | 2.11 | 0.08 |
| EPS Diluted Before Non-Recurring Items | 4.58 | 8.22 | 7.26 | 6.66 | 5.30 |
| EBITDA(a) | $19,476,000 | $16,691,000 | $13,580,000 | $9,237,000 | $7,586,000 |